107.39
Schlusskurs vom Vortag:
$113.74
Offen:
$102.46
24-Stunden-Volumen:
683.89K
Relative Volume:
1.14
Marktkapitalisierung:
$7.13B
Einnahmen:
$136.86M
Nettoeinkommen (Verlust:
$-168.69M
KGV:
-38.22
EPS:
-2.81
Netto-Cashflow:
$-113.49M
1W Leistung:
-5.51%
1M Leistung:
+8.27%
6M Leistung:
+67.49%
1J Leistung:
+102.32%
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Firmenname
Rhythm Pharmaceuticals Inc
Sektor
Branche
Telefon
857-264-4280
Adresse
222 BERKELEY STREET, BOSTON, MA
Vergleichen Sie RYTM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
RYTM
Rhythm Pharmaceuticals Inc
|
107.41 | 7.55B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.22 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
629.22 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.73 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.59 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.82 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-07-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-03-05 | Fortgesetzt | Stifel | Buy |
| 2025-01-02 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-21 | Eingeleitet | Guggenheim | Buy |
| 2024-09-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-17 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-05-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-08-08 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-05 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-06-17 | Bestätigt | Needham | Buy |
| 2022-03-02 | Fortgesetzt | Stifel | Buy |
| 2022-02-17 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | Fortgesetzt | Goldman | Neutral |
| 2021-08-04 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-08-04 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-01-08 | Eingeleitet | Goldman | Sell |
| 2019-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2019-07-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-03-13 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Overweight |
| 2018-06-25 | Bestätigt | Needham | Buy |
| 2018-06-15 | Bestätigt | Needham | Buy |
| 2017-10-30 | Eingeleitet | BofA/Merrill | Buy |
| 2017-10-30 | Eingeleitet | Needham | Buy |
Alle ansehen
Rhythm Pharmaceuticals Inc Aktie (RYTM) Neueste Nachrichten
Needham Raises Price Target for RYTM to $122, Maintains Buy Rati - GuruFocus
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates - Yahoo! Finance UK
Rhythm Pharmaceuticals’ Revenue Leaps On Rare Disease Drug Sales - Finimize
Rhythm Pharmaceuticals (RYTM) Exceeds Q3 Revenue Expectations - GuruFocus
Rhythm Pharmaceuticals Q3 2025 Earnings: Revenue Surpasses Estimates at $51.3M, EPS Misses with $0.82 Loss - GuruFocus
Earnings Flash (RYTM) Rhythm Pharmaceuticals, Inc. Reports Q3 Revenue $51.3M, vs. FactSet Est of $50.7M - MarketScreener
Rhythm Pharmaceuticals, Inc. Q3 Loss Increases, Misses Estimates - Nasdaq
Rhythm Pharma Q3 product revenue up 54% yr/yr on IMCIVREE sales - MarketScreener
Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update - TradingView
Why retail investors favor Rhythm Pharmaceuticals Inc. stockJuly 2025 Outlook & Fast Exit/Entry Strategy Plans - newser.com
[8-K] RHYTHM PHARMACEUTICALS, INC. Reports Material Event | RYTM SEC FilingForm 8-K - Stock Titan
Rhythm Pharma (NASDAQ: RYTM) Granted FDA Priority Review; PDUFA Dec. 20, 2025 - Stock Titan
Rhythm Pharmaceuticals Q3 2025 Earnings Preview - MSN
Is it time to cut losses on Rhythm Pharmaceuticals Inc.Market Trend Review & Community Shared Stock Ideas - newser.com
What to do if you’re stuck in Rhythm Pharmaceuticals Inc.Watch List & Verified Short-Term Plans - newser.com
Will Rhythm Pharmaceuticals Inc. price bounce be sustainableWeekly Earnings Recap & Low Volatility Stock Suggestions - newser.com
Can Rhythm Pharmaceuticals Inc. stock weather global recessionWeekly Stock Summary & Daily Volume Surge Signals - newser.com
Rhythm Pharmaceuticals, Inc. (RYTM) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
[Form 4] RHYTHM PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Will Rhythm Pharmaceuticals Inc. stock benefit from automationQuarterly Trade Summary & High Win Rate Trade Tips - newser.com
Visualizing Rhythm Pharmaceuticals Inc. stock with heatmapsWeekly Profit Report & Expert Approved Trade Ideas - newser.com
How resilient is Rhythm Pharmaceuticals Inc. stock in market downturnsWeekly Trade Review & Free Fast Entry Momentum Trade Alerts - newser.com
Is Rhythm Pharmaceuticals Inc. (1RV) stock supported by free cash flowJuly 2025 Breakouts & Long Hold Capital Preservation Plans - newser.com
Can machine learning forecast Rhythm Pharmaceuticals Inc. recoveryLong Setup & Weekly Top Performers Watchlists - newser.com
Can Rhythm Pharmaceuticals Inc. (1RV) stock hold up in economic slowdownCPI Data & Weekly Return Optimization Plans - newser.com
Is Rhythm Pharmaceuticals Inc. stock positioned for digital transformationWeekly Gains Summary & Step-by-Step Swing Trade Plans - newser.com
Is a relief rally coming for Rhythm Pharmaceuticals Inc. holdersJuly 2025 Institutional & Consistent Profit Alerts - newser.com
How currency fluctuations impact Rhythm Pharmaceuticals Inc. stockWeekly Risk Summary & Safe Capital Growth Stock Tips - newser.com
Published on: 2025-11-02 22:26:41 - newser.com
Is Rhythm Pharmaceuticals Inc. reversing from oversold territoryLayoff News & Free Long-Term Investment Growth Plans - newser.com
Rhythm Pharmaceuticals Hits New 52-Week High of $116.00 - Markets Mojo
Rhythm Pharmaceuticals, Inc. $RYTM Shares Sold by State of New Jersey Common Pension Fund D - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Sells $323,753.15 in Stock - MarketBeat
Finanzdaten der Rhythm Pharmaceuticals Inc-Aktie (RYTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):